Outcomes of genetic testing and prenatal diagnosis of spinal muscular atrophy in Jordan
Open Access
- 3 August 2025
- journal article
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 38 (1) , 2540463
Abstract
Spinal muscular atrophy (SMA) is a life-threatening, neuromuscular disease caused by variants in the survival motor neuron 1 (SMN1) gene, which affects spinal motor neurons resulting in progressive muscle weakness and hypotonia. This study aimed to identify the genetic diagnosis of SMA, present the outcomes of prenatal diagnosis, and provide an estimate for a minimum prevalence of the disease in Jordan. From 2007 through 2024, a total of 413 patients clinically suspected to have SMA and 243 at-risk prenatal cases were studied using diagnostic molecular testing. SMN1 exons 7 and 8 deletions were analyzed using either polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) (patients: n = 308, fetuses: n = 194) or multiplex ligation-dependent probe amplification (MLPA) (patients: n = 105, fetuses: n = 49). The copy number of SMN2 was determined for patients tested by MLPA. Homozygous deletion of SMN1 exon 7 was identified in 59.3% (245/413) of patients. Among them, 73.5% (n = 180) had SMA type I, 22.9% (n = 56) type II, and 3.7% (n = 9) type III. MLPA confirmed the diagnosis in 60% (63/105) of patients, with SMN2 copy numbers correlating with disease severity. A minimum prevalence of SMA was predicted to be 2.09 per 100,000 population with an incidence of 0.73 per 10,000 live births. Results on prenatal diagnostic cases showed 70.8% (172/243) of fetuses were unaffected. The study highlights the importance of SMA as a clinical health problem in Jordan and demonstrates MLPA as a reliable diagnostic tool. Our findings support the integration of SMA carrier screening into national newborn screening and premarital programs to enable early diagnosis, improve genetic counseling, and facilitate gene therapy options, ultimately improving overall patient outcomes and management.Keywords
Funding Information
- Jordan University of Science and Technology (0624/2023)
This publication has 39 references indexed in Scilit:
- A high-fidelity long-read sequencing-based approach enables accurate and effective genetic diagnosis of spinal muscular atrophyClinica Chimica Acta, 2023
- Studying carrier frequency of spinal muscular atrophy in the State of Qatar and comparison to other ethnic groups: Pilot studyMolecular Genetics & Genomic Medicine, 2023
- Application of a Multiplex Ligation-Dependent Probe Amplification-Based Next-Generation Sequencing Approach for the Detection of Pathogenesis of Duchenne Muscular Dystrophy and Spinal Muscular Atrophy Caused by Copy Number AberrationsMolecular Neurobiology, 2023
- New therapies for spinal muscular atrophy: where we stand and what is nextEuropean Journal of Pediatrics, 2023
- Comprehensive SMN1 and SMN2 profiling for spinal muscular atrophy analysis using long-read PacBio HiFi sequencingThe American Journal of Human Genetics, 2023
- Spinal muscular atrophy carrier frequency in Saudi ArabiaMolecular Genetics & Genomic Medicine, 2022
- Clinical phenotypes of spinal muscular atrophy patients with hybrid SMN geneBrain and Development, 2021
- Analytical validation of the droplet digital PCR assay for diagnosis of spinal muscular atrophyClinica Chimica Acta, 2020
- Structure and Organization of the Human Survival Motor Neurone (SMN) GeneGenomics, 1996
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995